Blue Shield of California will cover Plus Therapeutics’ CNSide CSF assay for metastatic CNS cancers starting April 2026, expanding total covered lives to 81 million, according to the company.
City of Hope will evaluate Quest Diagnostics’ Haystack MRD liquid biopsy in a multi-year trial, assessing its use for monitoring breast, colorectal, ovarian, and prostate cancers in about 500 patients across 14 US sites.
AI integrated into molecular profiling workflows identified misclassified lung cancer cases, highlighting its potential role in improving diagnostic accuracy in clinical labs.
The collaboration aims to create an innovation pipeline for specialized pediatric tests across oncology, metabolic disease, and autoimmune conditions.
Read More
The tool uses digitized pathology slides to estimate how patients will respond to therapy before surgery.
Read More
Researchers at MD Anderson have identified a blood-based biomarker using T cell receptor sequencing that may help assess cancer risk in asymptomatic Lynch syndrome carriers, according to a study in Nature Communications.
Read More
The clearance of the Onclarity HPV Self-Collection Kit and approval of the BD Onclarity HPV Assay aim to reduce barriers for unscreened populations.
Read More
20/20 BioLabs’ AI-powered multi-cancer early detection test, OneTest for Cancer, is now available to approximately 40,000 clinicians via the Evexia Diagnostics platform.
Read More
Biodesix will present seven abstracts—including two oral sessions—at AACR 2026, highlighting advances in automated myeloid testing, liquid biopsy, and NGS-based cancer monitoring platforms.
Read More
Data from nearly 1,900 SEER-linked patients show the test identifies meaningful survival differences within the same AJCC stage.
Read More
The updated urine test utilizes machine learning and patient ethnicity to provide individualized risk scores for aggressive disease.
Read More
A new survey-based study finds that more than half of physically Disabled women would prefer at-home human papillomavirus testing over traditional clinic-based cervical screening.
Read More
A new study validates a machine-learning platform that detects prostate cancer through biochemical patterns in urine samples.
Read More
Caris Life Sciences has launched Caris ChromoSeq, a whole genome and transcriptome sequencing assay for myeloid malignancies, designed to consolidate multiple tests into a single workflow with a seven-day turnaround.
Read More
Irish researchers have secured €670,000 to clinically validate a blood-based colorectal cancer screening test using inflammatory biomarkers, aiming for launch by 2027 through a new spin-out company.
Read More
The BiliSeq molecular test detected bile duct cancer in 82% of cases—compared to 44% with standard pathology—according to a six-year, multi-institutional study.
Read More
Using causal artificial intelligence and digital pathology, the test moves beyond population-level averages to predict patient-specific chemotherapy outcomes.
Read More
The collaboration pairs AI pathology algorithms with global laboratory infrastructure to help biopharma teams speed up evidence generation and diagnostic launch timelines.
Read More